ABOUT PII, A JABIL COMPANY
Pii, a Jabil company, is a contract development and manufacturing organization (CDMO) specializing in complex oral formulations. From its Hunt Valley, Maryland campus, Pii develops and manufactures tablets, capsules, softgels and oral liquids, including highly potent and DEA-controlled compounds, taking programs from first clinical batch to commercial supply on one site. State-of-the-art analytical and R&D laboratories support every program from formulation through release. Pii also offers aseptic manufacturing and sterile fill-finish. Combining more than 30 years of formulation expertise with Jabil’s global supply chain and operational excellence, Pii delivers big-company capability with the attention every program deserves.
Learn more at pharm-int.com.
THOUGHT LEADERSHIP
-
Complex formulations, HPAPIs, and modified-release products demand early planning. Formulation strategy, tech transfer, infrastructure, and partner selection largely determine scale-up success.
-
Many new drug candidates face oral bioavailability challenges. Particle engineering, lipid systems, and inclusion complexes can boost absorption, though patient variability remains a hurdle.
-
Early formulation decisions for high-viscosity, unstable, and potent molecules impact scale-up, regulatory flexibility, and lifecycle value. Getting them right early helps avoid costly rework.
CONTACT INFORMATION
Pii, A Jabil Company
10819 Gilroy Road
Hunt Valley, MD 21031
UNITED STATES
Fax: Brian_Boston@Jabil.com
Contact: Brian Boston
PROMOTIONAL CONTENT
-
Oral dose development, manufacturing, packaging, and serialization under one quality system, supporting potent and controlled compounds from clinical supply through commercial launch.
-
Integrated analytical testing keeps method development, release, and stability data aligned with manufacturing for potent, cytotoxic, and controlled-substance products across all phases.